Compare PGY & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PGY | PGEN |
|---|---|---|
| Founded | 2016 | 1998 |
| Country | United States | United States |
| Employees | 511 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | N/A | 2013 |
| Metric | PGY | PGEN |
|---|---|---|
| Price | $21.80 | $6.64 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $34.50 | $8.33 |
| AVG Volume (30 Days) | 3.1M | ★ 4.0M |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $230,981,000.00 |
| Revenue This Year | $14.27 | $1,115.92 |
| Revenue Next Year | $14.39 | $81.04 |
| P/E Ratio | $13.54 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.40 | $1.70 |
| 52 Week High | $44.99 | $6.70 |
| Indicator | PGY | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 71.95 | 72.02 |
| Support Level | $20.67 | $3.96 |
| Resistance Level | $25.47 | N/A |
| Average True Range (ATR) | 1.18 | 0.33 |
| MACD | 0.29 | 0.09 |
| Stochastic Oscillator | 98.40 | 95.64 |
Pagaya Technologies Ltd is a product-focused technology company. It uses machine learning, a vast data network, and an AI-driven approach to offer comprehensive consumer credit and residential real estate products for its partners, their customers, and investors. Its suite of products includes Decline Monetization, Dual Look, First Look, Affiliate Optimizer Engine, Direct Marketing Engine, and FastPass, providing lenders with an AI-powered credit and acquisition ecosystem that helps them approve more borrowers, capture more demand, and grow without adding risk. Geographically, the company generates maximum revenue from its business in the United States.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.